I assume there's also hurdles for generic manufacturers if all the combination Zan+Decitabine trials (approvals) were actually Zan+Inqovi trials?
It's a good question, @KingBuzzo. If I were Astex, I'd be looking for some of the upside in Zan to offset the inqovi portfolio risk.
I assume there's also hurdles for generic manufacturers if all...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.045(2.73%) |
Mkt cap ! $272.2M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.67 | $1.51 | $214.0K | 133.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 708 | $1.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 500 | 1 |
View Market Depth
| Last trade - 15.50pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.60 |
Change
-0.045 ( 2.74 %) |
||||
| Open | High | Low | Volume | ||
| $1.66 | $1.68 | $1.52 | 19707 | ||
| Last updated 15.48pm 04/06/2024 ? | |||||
| RAC (ASX) Chart |